BNP Paribas Financial Markets’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.6M | Sell |
540,499
-452,196
| -46% | -$14.5M | 0.01% | 1245 |
|
|
2025
Q4 | $34.9M | Buy |
992,695
+836,386
| +535% | +$29.6M | 0.02% | 870 |
|
|
2025
Q3 | $4.11M | Sell |
156,309
-11,714
| -7% | -$349K | ﹤0.01% | 2116 |
|
|
2025
Q2 | $4.45M | Sell |
168,023
-336,693
| -67% | -$8.86M | ﹤0.01% | 1934 |
|
|
2025
Q1 | $12.2M | Buy |
504,716
+458,015
| +981% | +$14.5M | 0.01% | 1296 |
|
|
2024
Q4 | $1.88M | Sell |
46,701
-40,011
| -46% | -$2.28M | ﹤0.01% | 2393 |
|
|
2024
Q3 | $5.49M | Sell |
86,712
-170,112
| -66% | -$9.98M | ﹤0.01% | 1452 |
|
|
2024
Q2 | $13.6M | Buy |
256,824
+178,410
| +228% | +$11.7M | 0.01% | 943 |
|
|
2024
Q1 | $6.43M | Sell |
78,414
-164,011
| -68% | -$7.3M | 0.01% | 1303 |
|
|
2023
Q4 | $4.51M | Sell |
242,425
-135,781
| -36% | -$1.78M | 0.01% | 1469 |
|
|
2023
Q3 | $4.19M | Sell |
378,206
-195,403
| -34% | -$2.79M | 0.01% | 1392 |
|
|
2023
Q2 | $9.3M | Buy |
573,609
+331,815
| +137% | +$6.95M | 0.01% | 942 |
|
|
2023
Q1 | $4.03M | Buy |
241,794
+192,051
| +386% | +$1.98M | 0.01% | 1375 |
|
|
2022
Q4 | $468K | Buy |
49,743
+49,431
| +15,843% | +$221K | ﹤0.01% | 2618 |
|
|
2022
Q3 | $849 | Sell |
312
-4,990
| -94% | -$16.3K | ﹤0.01% | 4450 |
|
|
2022
Q2 | $15.3K | Sell |
5,302
-4,904
| -48% | -$12.1K | ﹤0.01% | 3713 |
|
|
2022
Q1 | $30.6K | Sell |
10,206
-15,693
| -61% | -$56.3K | ﹤0.01% | 3659 |
|
|
2021
Q4 | $119K | Buy |
25,899
+8,569
| +49% | +$48K | ﹤0.01% | 3545 |
|
|
2021
Q3 | $109K | Buy |
17,330
+6,627
| +62% | +$40.9K | ﹤0.01% | 3239 |
|
|
2021
Q2 | $64.1K | Sell |
10,703
-23,551
| -69% | -$140K | ﹤0.01% | 3176 |
|
|
2021
Q1 | $217K | Buy |
34,254
+25,088
| +274% | +$177K | ﹤0.01% | 3004 |
|
|
2020
Q4 | $51.6K | Sell |
9,166
-6,173
| -40% | -$37.4K | ﹤0.01% | 3540 |
|
|
2020
Q3 | $89.3K | Buy |
15,339
+5,740
| +60% | +$39.5K | ﹤0.01% | 3180 |
|
|
2020
Q2 | $69.2K | Sell |
9,599
-32,251
| -77% | -$214K | ﹤0.01% | 2913 |
|
|
2020
Q1 | $196K | Buy |
41,850
+34,131
| +442% | +$210K | ﹤0.01% | 2865 |
|
|
2019
Q4 | $61.9K | Sell |
7,719
-2,065
| -21% | -$15.1K | ﹤0.01% | 3526 |
|
|
2019
Q3 | $67.3K | Buy |
9,784
+3,093
| +46% | +$23K | ﹤0.01% | 3333 |
|
|
2019
Q2 | $55.5K | Sell |
6,691
-5,990
| -47% | -$51.2K | ﹤0.01% | 3357 |
|
|
2019
Q1 | $126K | Buy |
+12,681
| New | +$106K | ﹤0.01% | 2985 |
|
|
2018
Q4 | – | Sell |
-1,424
| Closed | -$24.8K | – | 4430 |
|
|
2018
Q3 | $24.8K | Hold |
1,424
| – | – | ﹤0.01% | 3331 |
|
|
2018
Q2 | $13.5K | Buy |
+1,424
| New | +$9.47K | ﹤0.01% | 3657 |
|
Other funds holding VKTX
VCM
VPM
BNP Paribas Financial Markets's VKTX Position: Q1 2026 in Review
BNP Paribas Financial Markets reduced its Viking Therapeutics (VKTX) stake by 46% in Q1 2026, selling an estimated $14.5M and leaving 540,499 shares worth $17.6M. The position accounts for 0.01% of the portfolio, ranked #1245.
BNP Paribas Financial Markets first reported a position in VKTX in Q2 2018 and has held it in 31 quarters since. The position peaked at $34.9M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- BNP Paribas Financial Markets held 540,499 shares of Viking Therapeutics worth $17.6M as of Q1 2026.
- BNP Paribas Financial Markets sold 452,196 Viking Therapeutics shares in Q1 2026, an estimated $14.5M.
- Viking Therapeutics made up 0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #1245 holding.
- BNP Paribas Financial Markets first reported a position in Viking Therapeutics in Q2 2018 and has held it in 31 quarters since.
- BNP Paribas Financial Markets's Viking Therapeutics position peaked at $34.9M in Q4 2025.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.